The earnings call presented a mixed sentiment. While there were significant achievements such as the BARDA award and advancements in vaccine development, financial challenges and delays in clinical trials were also highlighted.
Company Guidance
In the GeoVax Fourth Quarter Full Year 2024 Corporate Update Call, the company provided guidance on several critical metrics and milestones for 2025. GeoVax announced its BARDA Project Next-Gen Award, valued at approximately $400 million, which supports the development of its next-generation COVID-19 vaccine, GEO-CM04S1. The company has confirmed all study sites and is advancing manufacturing processes to support the vaccine's clinical evaluation. They anticipate having the GEO-MVA vaccine, targeting Mpox and smallpox, ready for clinical evaluation in the latter half of 2025. For their Gedeptin cancer therapy, clinical operations are progressing with plans for a Phase II trial. Financially, GeoVax reported a net loss of $25 million for 2024, with revenues from the BARDA contract reaching $4 million. The company's cash balance stood at $5.5 million as of December 31, 2024, with strategic partnerships and financing activities planned to support ongoing development programs. The call also highlighted the company's commitment to addressing the unmet medical needs of immunocompromised populations with their COVID-19 vaccine and their strategic focus on establishing business partnerships for global development and distribution.
BARDA Project Next-Gen Award
GeoVax secured a $400 million award from BARDA for the development of the next-generation COVID-19 vaccine GEO-CM04S1, with the program underway and study sites confirmed.
Advancements in GEO-MVA Vaccine
Completion of cGMP product and quality release for GEO-MVA, GeoVax's vaccine candidate against Mpox and Smallpox, with sufficient product produced for clinical evaluation.
Increase in R&D Spending
Research and development expenses increased by 14% to $23.7 million in 2024, mainly due to the BARDA contract and manufacturing clinical trial materials.
Potential for Strategic Partnerships
GeoVax is focusing on establishing partnerships and collaborations for global development and commercialization of its vaccines.
---
GeoVax Labs (GOVX) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GOVX Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Mar 27, 2025
$1.27
$1.11
-12.60%
Nov 12, 2024
$3.25
$2.70
-16.92%
Aug 06, 2024
$1.80
$1.78
-1.11%
May 14, 2024
$1.70
$1.72
+1.18%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does GeoVax Labs (GOVX) report earnings?
GeoVax Labs (GOVX) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is GeoVax Labs (GOVX) earnings time?
GeoVax Labs (GOVX) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.